Voretigen Neparvovec (2, reassessment) (Luxturna®) – Hereditary retinal dystrophy
Characteristics
| Start date | 01.04.2022 |
|---|---|
| Resolution | 15.09.2022 – active procedure |
| INN | Voretigen Neparvovec |
| Brand name | Luxturna® |
| Pharm. company | Novartis Pharma GmbH |
| Therapeutic area | Eye diseases ORPHAN |
| Reason for procedure |
Reassessment: G-BA limitation
Original resolution: Voretigen Neparvovec (17.10.2019) |
Associated procedures
| Resolution | INN | Brand name | Indication | Patients | Additional benefit |
|---|---|---|---|---|---|
| 15.04.2019 – 17.10.2019 | Voretigen Neparvovec | Luxturna® | Hereditary retinal dystrophy | 100 – 530 | |
| 01.04.2022 – 15.09.2022 | Voretigen Neparvovec (2, reassessment) | Luxturna® | Hereditary retinal dystrophy | n.d. |
<< List of all resolutions